MIM
PRTK

MetLife Investment Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

MetLife Investment Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4,634
Closed -$32.7K – 2509
2021
Q1 		$32.7K Sell
4,634
-16,106
-78% -$116K ﹤0.01% 2293
2020
Q4 		$130K Sell
20,740
-463
-2% -$2.73K ﹤0.01% 2184
2020
Q3 		$115K Sell
21,203
-270
-1% -$1.34K ﹤0.01% 2154
2020
Q2 		$112K Buy
+21,473
New +$95.4K ﹤0.01% 2204
2018
Q4 		– Sell
-16,222
Closed -$157K – 2605
2018
Q3 		$157K Hold
16,222
– – ﹤0.01% 2219
2018
Q2 		$165K Buy
16,222
+5,895
+57% +$66.7K ﹤0.01% 2010
2018
Q1 		$134K Hold
10,327
– – ﹤0.01% 2088
2017
Q4 		$185K Buy
+10,327
New +$215K ﹤0.01% 1976

Other funds holding PRTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MetLife Investment Management's PRTK Position: Q2 2021 in Review

MetLife Investment Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2021, closing a stake of 4,634 shares — an estimated $32.7K sold.

MetLife Investment Management first reported a position in PRTK in Q4 2017 and held it in 8 quarters. The position peaked at $185K in Q4 2017. 116 funds tracked by Wall St. Rank hold PRTK as of Q2 2021.

  • MetLife Investment Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • MetLife Investment Management sold 4,634 Paratek Pharmaceuticals, Inc. shares in Q2 2021, an estimated $32.7K.
  • MetLife Investment Management first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2017 and held it in 8 quarters.
  • MetLife Investment Management's Paratek Pharmaceuticals, Inc. position peaked at $185K in Q4 2017.
  • 116 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2021.

Based on MetLife Investment Management's 13F filing for Q2 2021, filed 16 Aug 2021.